|
|
|
|
|
|
|
Mon T W Th F |
|
11 May, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nicole DeFeudis noticed something in Madrigal Pharmaceuticals’ earnings last week: Sales of the company’s MASH drug Rezdiffra didn’t appear to face as much competition from Wegovy — now approved in MASH — as investors feared. She dug into what happened instead, and what that might mean for the future of the market. |
|
|
|
Lydia Ramsey Pflanzer |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
Bill Sibold, Madrigal Pharmaceuticals CEO |
|
|
|
by Nicole DeFeudis
|
It seems there’s room for two in the MASH market. When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues. The drugmaker published a... | |
|
|
|
|
|
|
|
|
by Elizabeth Cairns
|
CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by about 4% and said it would... | |
|
|
|
|
|
|
by Ryan Cross
|
Drug developers are racing to make gene therapiesthat could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same... | |
|
|
|
|
|
|
by Max Gelman
|
San Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank... | |
|
|
|
